Imaging AD pathology also includes the use of amyloid imaging tracers such as Pittsburgh Compound-B (PiB), as well as three amyloid radiotracers AmyvidTM (florbetapir F18), NeuraceqTM (florbetaben F18) and VizamylTM (flutemetamol F18) and one tau ligand (TauvidTM; 18F-flortaucipir) that are now approved by the Food and Drug Administration (FDA) [108]. This evidence concerns the gene MAPT and Alzheimer disease.